ASXL1 and acute myeloid leukemia: In conclusion, patients with mutations in SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 constitute a substantial proportion of patients diagnosed with AML, NOS or with AML-MRC-MLD.